| scholarly article | Q13442814 |
| P50 | author | Luis Miguel Ruilope | Q56550076 |
| P2093 | author name string | Giancarlo Viberti | |
| Kenneth Jamerson | |||
| Johannes F E Mann | |||
| ASCEND Study Group | |||
| Damian Green | |||
| Susan J Kuranoff | |||
| Thomas Littke | |||
| P2860 | cites work | Avosentan reduces albumin excretion in diabetics with macroalbuminuria | Q24642372 |
| Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | Q28188162 | ||
| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy | Q29615215 | ||
| Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data | Q30656350 | ||
| Endothelin in cardiovascular control: the role of endothelin antagonists | Q34028145 | ||
| Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes | Q34331403 | ||
| Assessing kidney function--measured and estimated glomerular filtration rate | Q34535861 | ||
| Endothelin receptor antagonists in heart failure: current status and future directions | Q35771475 | ||
| Clinical trials of endothelin antagonists in heart failure: a question of dose? | Q36495006 | ||
| Antihypertensive therapy in the presence of proteinuria | Q36690664 | ||
| Reversal of proteinuric renal disease and the emerging role of endothelin. | Q37224296 | ||
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. | Q40509707 | ||
| Endothelin A receptor antagonism and angiotensin-converting enzyme inhibition are synergistic via an endothelin B receptor-mediated and nitric oxide-dependent mechanism | Q45091466 | ||
| Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values | Q45119840 | ||
| Efficacy and safety of darusentan: a novel endothelin receptor antagonist. | Q45973623 | ||
| Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects | Q46091583 | ||
| The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension | Q46169157 | ||
| Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. | Q51022288 | ||
| Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. | Q52965921 | ||
| Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis | Q71108539 | ||
| Effect of BQ-123, an endothelin antagonist, on renal hemodynamics, tubular function, vasoactive hormones, and blood pressure in healthy humans: a dose response study | Q81644934 | ||
| Multiple-dose pharmacokinetics, pharmacodynamics and tolerability of the oral ET(A) endothelin-receptor antagonist SPP301 in man | Q81869478 | ||
| P433 | issue | 3 | |
| P304 | page(s) | 527-535 | |
| P577 | publication date | 2010-02-18 | |
| P1433 | published in | Journal of the American Society of Nephrology | Q17123893 |
| P1476 | title | Avosentan for overt diabetic nephropathy | |
| P478 | volume | 21 |
| Q39038570 | A perspective on chronic kidney disease progression |
| Q58134776 | Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone |
| Q42878981 | Acid retention during kidney failure induces endothelin and aldosterone production which lead to progressive GFR decline, a situation ameliorated by alkali diet. |
| Q34726905 | Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy |
| Q33983807 | Advances in the pathophysiology of pre-eclampsia and related podocyte injury |
| Q41085057 | Advantages of a wholly Bayesian approach to assessing efficacy in early drug development: a case study |
| Q35682234 | Albuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View |
| Q35895257 | Antidiuretic effects of the endothelin receptor antagonist avosentan. |
| Q38658961 | Association between Endothelin-1 Levels and Kidney Disease among Blacks |
| Q39106330 | Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials |
| Q93161172 | Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial |
| Q38806647 | Atrasentan for the treatment of diabetic nephropathy. |
| Q92940784 | Atrasentan in patients with diabetes and chronic kidney disease |
| Q92940804 | Atrasentan in patients with diabetes and chronic kidney disease - Authors' reply |
| Q50198506 | Bardoxolone Methyl Improves Kidney Function in Patients with Chronic Kidney Disease Stage 4 and Type 2 Diabetes: Post-Hoc Analyses from Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes Study |
| Q34383685 | Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease |
| Q85734297 | Can two be better than one? Dual RAS blockade in patients with type 2 diabetes and overt nephropathy in the age of ONTARGET and ALTITUDE |
| Q64915448 | Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan? |
| Q38010045 | Cellular and molecular mechanisms of diabetic glomerulopathy |
| Q38248855 | Challenges and opportunities in the development of therapeutics for chronic kidney disease |
| Q38609767 | Chinese medicines in the treatment of experimental diabetic nephropathy. |
| Q35207830 | Chronic blockade of endothelin A and B receptors using macitentan in experimental renovascular disease |
| Q38087529 | Chronic kidney disease: a new look at pathogenetic mechanisms and treatment options |
| Q34360718 | Combined endothelin a blockade and chlorthalidone treatment in a rat model of metabolic syndrome |
| Q38502138 | Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis |
| Q34632600 | Critical appraisal of the differential effects of antihypertensive agents on arterial stiffness. |
| Q38225794 | Current state of endothelin receptor antagonism in hypertension and pulmonary hypertension |
| Q58557086 | DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGS |
| Q51731812 | Defining the Optimal Dose of Atrasentan by Evaluating the Exposure-Response Relationships of Albuminuria and Bodyweight. |
| Q55476982 | Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD). |
| Q38781550 | Developing Treatments for Chronic Kidney Disease in the 21st Century |
| Q28086840 | Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets |
| Q27021392 | Diabetic kidney disease: from physiology to therapeutics |
| Q28742785 | Diabetic nephropathy - Epidemiology in Asia and the current state of treatment |
| Q34387952 | Diabetic nephropathy - complications and treatment |
| Q84601303 | Diabetic nephropathy: Endothelin antagonism for diabetic nephropathy |
| Q38150065 | Diabetic nephropathy: diagnosis and treatment |
| Q38338539 | Diabetic nephropathy: landmark clinical trials and tribulations |
| Q58712499 | Diabetic nephropathy: newer therapeutic perspectives |
| Q34502911 | Disruption of the endothelin A receptor in the nephron causes mild fluid volume expansion |
| Q38654327 | Drug therapies to delay the progression of chronic kidney disease |
| Q38553911 | Drugs meeting the molecular basis of diabetic kidney disease: bridging from molecular mechanism to personalized medicine. |
| Q26752292 | Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease |
| Q34604473 | Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease |
| Q36610325 | ET-1 actions in the kidney: evidence for sex differences |
| Q64965105 | Effect of PF-04634817, an Oral CCR2/5 Chemokine Receptor Antagonist, on Albuminuria in Adults with Overt Diabetic Nephropathy. |
| Q37741992 | Effect of berberine on the renal tubular epithelial-to-mesenchymal transition by inhibition of the Notch/snail pathway in diabetic nephropathy model KKAy mice |
| Q34787799 | Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial |
| Q44392807 | Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial |
| Q57299063 | Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events in patients with diabetes and overt nephropathy: a meta-analysis of randomised controlled trials |
| Q99210879 | Effects of the dual endothelin receptor antagonist aprocitentan on body weight and fluid homeostasis in healthy subjects on a high sodium diet |
| Q64885015 | Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial. |
| Q47136700 | Efficacy and Safety of Niaoduqing Particles for Delaying Moderate-to-severe Renal Dysfunction: A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Study |
| Q46399341 | Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET). |
| Q28546969 | Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial |
| Q34420383 | Emerging drugs for chronic kidney disease |
| Q38075029 | Emerging drugs for managing kidney disease in patients with diabetes. |
| Q37251105 | Endothelial-podocyte crosstalk: the missing link between endothelial dysfunction and albuminuria in diabetes |
| Q26767156 | Endothelin |
| Q26799476 | Endothelin Blockade in Diabetic Kidney Disease |
| Q38525983 | Endothelin Receptor Antagonists: New Hope for Renal Protection? |
| Q90522780 | Endothelin Receptor Antagonists: Status Quo and Future Perspectives for Targeted Therapy |
| Q34437692 | Endothelin and endothelin antagonists in chronic kidney disease |
| Q35452282 | Endothelin and the podocyte |
| Q38185016 | Endothelin antagonism for patients with chronic kidney disease: still a hope for the future |
| Q37219055 | Endothelin antagonists for diabetic and non-diabetic chronic kidney disease |
| Q42547440 | Endothelin antagonists in diabetic nephropathy: back to basics |
| Q38052428 | Endothelin antagonists in hypertension and kidney disease |
| Q35050553 | Endothelin receptor a blockade is an ineffective treatment for adriamycin nephropathy |
| Q42421661 | Endothelin receptor antagonists in proteinuric renal disease: every rose has its thorn |
| Q36098922 | Endothelin receptor-A antagonist attenuates retinal vascular and neuroretinal pathology in diabetic mice. |
| Q27023208 | Endothelin receptors and their antagonists |
| Q37244292 | Endothelin, kidney disease, and hypertension |
| Q41041170 | Endothelin-1 Drives Epithelial-Mesenchymal Transition in Hypertensive Nephroangiosclerosis |
| Q39879255 | Endothelin-1 Induces Proteinuria by Heparanase-Mediated Disruption of the Glomerular Glycocalyx |
| Q35549144 | Endothelin-1 critically influences cardiac function via superoxide-MMP9 cascade |
| Q36301714 | Endothelin-1 gene polymorphisms and diabetic kidney disease in patients with type 2 diabetes mellitus |
| Q40493852 | Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis |
| Q51000648 | Endothelin-receptor antagonists for diabetic nephropathy: A meta-analysis. |
| Q90416209 | Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition |
| Q36701565 | Enhanced vascular chymase-dependent conversion of endothelin in the diabetic kidney |
| Q35647853 | Epigenetics in diabetic kidney disease |
| Q38784727 | First-in-Man Demonstration of Direct Endothelin-Mediated Natriuresis and Diuresis |
| Q35178609 | Flow regulation of endothelin-1 production in the inner medullary collecting duct |
| Q30234704 | Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy |
| Q39112475 | Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment |
| Q35086477 | Glomerular endothelial cell injury and cross talk in diabetic kidney disease |
| Q50961858 | Glomerular haemodynamic profile of patients with Type 1 diabetes compared with healthy control subjects. |
| Q90632374 | Glucose and Blood Pressure-Dependent Pathways-The Progression of Diabetic Kidney Disease |
| Q35719874 | Gq signaling causes glomerular injury by activating TRPC6. |
| Q38189884 | Have we reached the limits for the treatment of diabetic nephropathy? |
| Q26799443 | Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade |
| Q35953909 | Hypertension Management in Diabetic Kidney Disease |
| Q37833490 | Hypertension in 2010: Blood pressure and the kidney |
| Q35203404 | Hypertension in Cardiovascular and Kidney Disease |
| Q37827620 | Hypertension in diabetic nephropathy: epidemiology, mechanisms, and management |
| Q33167828 | Idiopathic pre-capillary pulmonary hypertension in patients with end-stage kidney disease: effect of endothelin receptor antagonists |
| Q104499896 | Individual atrasentan exposure is associated with long-term kidney and heart failure outcomes in patients with type 2 diabetes and chronic kidney disease |
| Q89658327 | Inflammatory Targets in Diabetic Nephropathy |
| Q51092133 | Insulin Inhibits Nrf2 Gene Expression via Heterogeneous Nuclear Ribonucleoprotein F/K in Diabetic Mice. |
| Q52685042 | JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. |
| Q39035802 | Kidney Fibrosis: Origins and Interventions |
| Q91046009 | Kidney disease trials for the 21st century: innovations in design and conduct |
| Q36783886 | Limitations and future treatment options in type 2 diabetes with renal impairment |
| Q42370964 | Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial |
| Q37364008 | Matrix Producing Cells in Chronic Kidney Disease: Origin, Regulation, and Activation. |
| Q90470119 | Microalbuminuria and cardiorenal risk: old and new evidence in different populations |
| Q37899907 | New approaches to the treatment of nephropathy in diabetes |
| Q37964276 | New options and perspectives for proteinuria management after kidney transplantation. |
| Q90719496 | New pharmacological strategies for protecting kidney function in type 2 diabetes |
| Q37559164 | New therapeutic agents in diabetic nephropathy |
| Q47395215 | Novel avenues for drug discovery in diabetic kidney disease |
| Q37219043 | Novel drugs and intervention strategies for the treatment of chronic kidney disease |
| Q38265818 | Novel effective drugs for diabetic kidney disease? or not? |
| Q37773166 | Obesity and aging: determinants of endothelial cell dysfunction and atherosclerosis. |
| Q35859738 | Obesity and risk of vascular disease: importance of endothelium-dependent vasoconstriction |
| Q37904098 | Off the beaten renin-angiotensin-aldosterone system pathway: new perspectives on antiproteinuric therapy |
| Q38821323 | Osmolar regulation of endothelin-1 production by the inner medullary collecting duct |
| Q64095815 | Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons |
| Q42722900 | Phosphodiesterase Type 5 Inhibition Reduces Albuminuria in Subjects with Overt Diabetic Nephropathy |
| Q38186986 | Potential approaches to reverse or repair renal fibrosis |
| Q40675012 | Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers |
| Q36025568 | Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy |
| Q37621556 | Predictors of congestive heart failure after treatment with an endothelin receptor antagonist |
| Q26864133 | Present and future in the treatment of diabetic kidney disease |
| Q37964266 | Proteinuria: detection and role in native renal disease progression |
| Q89733315 | Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension |
| Q48098900 | Rationale and protocol of the Study of Diabetic Nephropathy with Atrasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy |
| Q42272174 | Rationale and trial design of Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes: the Occurrence of Renal Events (BEACON). |
| Q52613060 | Renal aquaporin-4 associated pathology in TG-26 mice. |
| Q28082365 | Renal autoregulation in health and disease |
| Q35673442 | Renal hyperfiltration related to diabetes mellitus and obesity in human disease |
| Q38219634 | Renal neurohormonal regulation in heart failure decompensation. |
| Q51100638 | Renin-angiotensin system blockade alone or combined with ETA receptor blockade: effects on the course of chronic kidney disease in 5/6 nephrectomized Ren-2 transgenic hypertensive rats. |
| Q37234978 | Role of collecting duct endothelin in control of renal function and blood pressure |
| Q92885442 | SONAR propels endothelin A receptor antagonists to success |
| Q38221725 | Selective endothelin inhibition in diabetic nephropathy: is it the icing on the cake? |
| Q34625011 | Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial |
| Q33873241 | Slowing progression of chronic kidney disease |
| Q47614541 | Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials |
| Q91796100 | Study Design of the Phase 3 Sparsentan Versus Irbesartan (DUPLEX) Study in Patients With Focal Segmental Glomerulosclerosis |
| Q89539962 | The Role of Endothelin and Endothelin Antagonists in Chronic Kidney Disease |
| Q89521015 | The SONAR study-is there a future for endothelin receptor antagonists in diabetic kidney disease? |
| Q36958430 | The cardiovascular physiology and pharmacology of endothelin-1. |
| Q41989543 | The diabetes pandemic suggests unmet needs for 'CKD with diabetes' in addition to 'diabetic nephropathy'-implications for pre-clinical research and drug testing |
| Q28237978 | The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy |
| Q40013771 | The endothelin receptor antagonist bosentan improves peripheral endothelial function in patients with type 2 diabetes mellitus and microalbuminuria: a randomised trial. |
| Q38843815 | The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction. |
| Q35760302 | The kidney in type 2 diabetes therapy |
| Q38845590 | The next generation of therapeutics for chronic kidney disease |
| Q33358784 | The paradox of bardoxolone methyl: a call for every witness on the stand? |
| Q38209811 | Therapeutic approaches to diabetic nephropathy--beyond the RAS. |
| Q38196857 | Therapeutic implications of peptide interactions with G-protein-coupled receptors in diabetic vasculopathy |
| Q27007027 | Therapeutic modalities in diabetic nephropathy: standard and emerging approaches. |
| Q38678678 | Therapeutic potential of endothelin receptor antagonism in kidney disease |
| Q35079607 | Therapeutic targets for treating fibrotic kidney diseases |
| Q38605099 | Therapies on the Horizon for Diabetic Kidney Disease. |
| Q90256327 | Time for clinical decision support systems tailoring individual patient therapy to improve renal and cardiovascular outcomes in diabetes and nephropathy |
| Q57189957 | Treating diabetic complications; from large randomized clinical trials to precision medicine |
| Q27694623 | Treatment of chronic kidney disease |
| Q33907249 | Treatment of diabetic kidney disease: current and future targets |
| Q36297539 | Twenty years after ACEIs and ARBs: emerging treatment strategies for diabetic nephropathy |
| Q89398640 | Unmet need in diabetic nephropathy: failed drugs or trials? |
| Q39152873 | Upcoming drugs for the treatment of preeclampsia in pregnant women |
| Q88739091 | Update on Endothelin Receptor Antagonists in Hypertension |
| Q37980677 | What are new avenues for renal protection, in addition to RAAS inhibition? |
Search more.